Our top pick for
IVERIC bio, Inc is a biotechnology business based in the US. IVERIC bio shares (ISEE) are listed on the NASDAQ and all prices are listed in US Dollars. IVERIC bio employs 55 staff and has a market cap (total outstanding shares value) of USD$622.5 million.
|Latest market close||USD$7.5|
|52-week range||USD$2.64 - USD$8.97|
|50-day moving average||USD$6.6185|
|200-day moving average||USD$5.5082|
|Wall St. target price||USD$13|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$1.527|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-09)||N/A|
|1 month (2020-12-18)||7.5|
|3 months (2020-10-16)||17.55%|
|6 months (2020-07-17)||64.84%|
|1 year (2020-01-17)||10.62%|
|2 years (2019-01-18)||439.57%|
|3 years (2018-01-18)||155.10%|
|5 years (2016-01-16)||N/A|
Valuing IVERIC bio stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IVERIC bio's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
IVERIC bio's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, IVERIC bio shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Gross profit TTM||USD$-39,644,000|
|Return on assets TTM||-30.4%|
|Return on equity TTM||-50.38%|
|Market capitalisation||USD$622.5 million|
TTM: trailing 12 months
There are currently 3.7 million IVERIC bio shares held short by investors – that's known as IVERIC bio's "short interest". This figure is 2.4% up from 3.7 million last month.
There are a few different ways that this level of interest in shorting IVERIC bio shares can be evaluated.
IVERIC bio's "short interest ratio" (SIR) is the quantity of IVERIC bio shares currently shorted divided by the average quantity of IVERIC bio shares traded daily (recently around 689387.10865562). IVERIC bio's SIR currently stands at 5.43. In other words for every 100,000 IVERIC bio shares traded daily on the market, roughly 5430 shares are currently held short.
However IVERIC bio's short interest can also be evaluated against the total number of IVERIC bio shares, or, against the total number of tradable IVERIC bio shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IVERIC bio's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 IVERIC bio shares in existence, roughly 40 shares are currently held short) or 0.0475% of the tradable shares (for every 100,000 tradable IVERIC bio shares, roughly 48 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against IVERIC bio.
Find out more about how you can short IVERIC bio stock.
We're not expecting IVERIC bio to pay a dividend over the next 12 months.
Over the last 12 months, IVERIC bio's shares have ranged in value from as little as $2.64 up to $8.97. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IVERIC bio's is 1.632. This would suggest that IVERIC bio's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
IVERIC bio, Inc., a biopharmaceutical company, develops novel therapies to treat ophthalmic diseases with a focus on age-related and orphan retinal diseases. The company is developing Zimura, an inhibitor of complement factor C5, which is in Phase IIb clinical trials for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration. It is also developing High temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases. The company has a license agreement with the University of Florida Research Foundation and the University of Pennsylvania for the development and commercialization of novel adeno-associated virus gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and Best disease and other BEST1-related inherited retinal diseases. It also has a research agreement with the University of Massachusetts Medical School to develop gene therapy product candidates targeting Leber Congenital Amaurosis type 10 and autosomal recessive Stargardt disease; and IRDs associated with mutations in the USH2A gene. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. IVERIC bio, Inc. was founded in 2007 and is headquartered in New York, New York.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.